How 5-fluorouracil acts;Jak działa 5-flourouracyl

Wspolczesna Onkologia

Volumn 9, Issue 10, 2005, Pages 414-423

  Wawrocka Pawlak, Marlena ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

5 Flourouracil; Apoptosis; Cancer; DNA damage; p53; Thymidylate synthase

Indexed keywords

5 FLOUROURIDINE TRIPHOSPHATE; 5 FLUORO 2' DEOXIURIDINE TRIPHOSPHATE; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE; DRUG METABOLITE; FLUOROURACIL; METHYLENETETRAHYDROFOLIC ACID; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE PROGRESSION; COLORECTAL CANCER; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 30844449883     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Sun W, Haller DG. Adjuvant therapy of colon cancer. Semin Oncol 2005; 32: 95-102.
2. Zhu AX, Willett CG. Combined modality treatment for rectal cancer. Semin Oncol 2005; 32: 103-12.
3. Dickson JL, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004; 16: 255-63.
4. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 2003; 29: 525-32.
5. Jaiyesimi I. Chemotherapy regimens for breast cancer. W: Cancer Management: A Multidisciplinary Approach. Pazdur R, Coia LR, Hoskins WJ, Wagman LD (red.). PRR, Inc., Melville, NY 2002; 213-7.
6. Okusaka T, Kosuge T. Systemic chemotherapy for pancreatic cancer. Pancreas 2004; 28: 301-4.
7. Fanucchi M, Khuri FR. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 2004; 31: 809-15.
8. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004; 31: 778-85.
9. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-32.
10. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19: 1541-3.
11. Page R. Principles of chemotherapy. W: Cancer Management: A Multidisciplinary Approach. Pazdur R, Coia LR, Hoskins WJ, Wagman LD (red.). PRR, Inc., Melville, NY 2002; 21-36.
12. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727-40.
13. Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981; 4: 633-49.
14. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119-25.
15. Dizon DS, Kemeny NE. Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol 2002; 29: 126-35.
16. Barber FD, Mavligit G, Kurzrock R. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 2004; 30: 425-36.
17. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
18. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48 (3): 381-95.
19. Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19: 437-43.
20. Schilsky RL. Antimetabolites. In: The Chemotherapy Source Book. Perry MC (red.). Williams & Wilkins, Baltimore 1992; 301-15.
21. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063-74.
22. Ingraham HA, Tseng BY, Goulian M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol 1982; 21: 211-6.
23. Mauro DJ, De Riel JK, Tallarida RJ, Sirover MA. Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells. Mol Pharmacol 1993; 43: 854-7.
24. Dolnick BJ, Wu XP. Effects of 5-fluorouracil on mRNA. Adv Exp Med Biol 1993; 339: 57-63; discussion 65.
25. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
26. Kufe DW, Major PP. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 1981; 256: 9802-5.
27. Doong SL, Dolnick BJ. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem 1988; 263: 4467-73.
28. Will CL, Dolnick BJ. 5-Fluorouracil inhibits dihydrofolate reductase precursor mRNA processing and/or nuclear mRNA stability in methotrexate-resistant KB cells. J Biol Chem 1989; 264: 21413-21.
29. Patton JR. Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry 1993; 32: 8939-44.
30. Wu XP, Dolnick BJ. 5-Fluorouracil alters dihydrofolate reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction. Mol Pharmacol 1993; 44: 22-9.
31. Ghoshal K, Jacob ST. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 1994; 54: 632-6.
32. Ghoshal K, Jacob ST. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol 1997; 53: 1569-75.
33. Kunkel TA, Bebenek K. DNA replication fidelity. Annu Rev Biochem 2000; 69: 497-529.
34. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1: 22-33.
35. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999; 286: 1897-1905.
36. Zhou B-BS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-439.
37. Walker GC. Understanding the complexity of an organism's responses to DNA damage. Cold Spring Harb Symp Quant Biol 2000; 65: 1-10.
38. Savitsky K, Bar-Shira A, Gilad S, i wsp. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268: 1749-53.
39. Gatti RA, Becker-Catania S, Chun HH, i wsp. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol 2001; 20: 87-108.
40. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT. A role of ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999; 13: 152-7.
41. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-9.
42. Bakkenist CJ, Kastan MB. (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506.
43. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003; 22: 5612-21.
44. Roos-Mattjus P, Vroman BT, Burtelow MA, Rauen M, Eapen AK, Karnitz LM. Genotoxin-induced Rad9-Hus1-Rad1 (9-1-1) chromatin association is an early checkpoint signaling event. J Biol Chem 2002; 277: 43809-12.
45. Zou L, Cortez D, Elledge SJ. Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev 2002; 16: 198-208.
46. Bermudez VP, Lindsey-Boltz LA, Cesare AJ, Maniwa Y, Griffith JD, Hurwitz J, Sancar A. Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. Proc Natl Acad Sci U S A 2003; 100: 1633-8.
47. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001; 21: 4129-39.
48. Bartek J, Falck J, Lukas J. CHK2 kinase - a busy messenger. Nat Rev Mol. Cell Biol 2001; 2: 877-86.
49. Ahn JY, Li X, Davis HL, Canman CE. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. Biol Chem 2002; 277: 19389-95.
50. Groth A, Hansen K, Nigg EA, Sillje HHW, Lukas J, and Bartek J. Human tousled like kinases are targeted by an ATM and Chk1 dependent DNA damage checkpoint. EMBO J 2003; 22: 1676-87.
51. Xie S, Wu H, Wang Q, Kunicki J, Thomas RO, Hollingsworth RE, Cogswell J, Dai W. Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2. Cell Cycle 2002; 1: 424-9.
52. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 2002; 4: 865-70.
53. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003; 5: 401-9.
54. Sampath D, Shi Z, Plunkett W. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol Pharmacol 2002; 62: 680-8.
55. Liu Q, Guntuku S, Cui XS, i wsp. Chk1 is an essential kinase that is regulated by Atr and required for the G (2) /M DNA damage checkpoint. Genes Dev 2000; 14: 1448-59.
56. Hirao A, Cheung A, Duncan G. i wsp. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM) -dependent and an ATM-independent manner. Mol Cell Biol 2002; 22: 6521-32.
57. Kastan MB, Lim DS, Kim ST, Xu B, Canman C. Multiple signaling pathways involving ATM. Cold Spring Harb Symp Quant Biol 2000; 65: 521-6.
58. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996; 274: 1664-72.
59. McGowan CH, Russell P. The DNA damage response: sensing and signaling. Curr Opin Cell Biol 2004; 16: 629-33.
60. Pawlak WZ, Wawrocka-Pawlak M, Szczylik C. Biologia molekularna czerniaka skóry. Współczesna Onkologia 2003; 7: 548-555.
61. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-501.
62. Ljungman M. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress. Neoplasia 2000; 2: 208-25.
63. Takai N, Hamanaka R, Yoshimatsu I, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005 Jan 10; 24 (2): 287-91.
64. Green D. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102: 1-4.
65. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev Cancer 2002; 3: 420-30.
66. Adams J, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
67. Hunt A, Evan G. Till death us do part. Science 2001; 293: 1784-5.
68. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
69. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
70. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-9.
71. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10: 2158-67.
72. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S. Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines. Int J Oncol 2005; 26: 1563-7.
73. Lee BJ, Chon KM, Kim YS, An WG, Roh HJ, Goh EK, Wang SG. Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line. Chemotherapy 2005; 51: 103-10.
74. Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 1998; 5: 203-8.
75. Boku N, Chin K, Hosokawa K, i wsp. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998; 4: 1469-74.
76. Wong CS, Tsao MS, Sharma V, Chapman WB, Pintilie M, Cummings BJ. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1999; 45: 309-14.
77. Cabelguenne A, Blons H, de Waziers I, i wsp. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000; 18: 1465-73.
78. Szumilo J, Chibowski D, Dabrowski A. Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma. Dis Esophagus 2000; 13: 191-7. Errata in: Dis Esophagus 2000; 13: 333.
79. Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Peters GJ. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 2001; 12: 779-85.
80. Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 2004; 25: 258-63.
81. Andersson J, Larsson L, Klaar S, i wsp. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 2005; 16: 743-8.
82. Jiang S, Song MJ, Shin EC, Lee MO, Kim SJ, Park JH. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology 1999; 29: 101-10.
83. Tillman DM, Petak I, Houghton JA. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999; 5: 425-30.
84. Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida B. Chemo-immunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol Rep 1999; 6: 979-82.
85. Petak I, Tillman DM, Houghton JA. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 2000; 6: 4432-41.
86. Backus HH, Dukers DF, van Groeningen CJ, i wsp. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 2001; 12: 209-16.
87. Iwase M, Watanabe H, Kondo G, Ohashi M, Nagumo M. Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 2003; 106: 619-25.
88. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004; 172: 4599-608.
89. Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 2001; 7: 1111-7. Errata w: Nat Med 2001; 7: 1255.
90. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA; 93: 11848-52.
91. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-5.
92. Lee JM. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. Oncogene 1998; 17: 1653-62.
93. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999; 18: 6027-36.
94. Liu G, Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 2002; 21: 7195-204.
95. Adeyemo D, Imtiaz F, Toffa S, Lowdell M, Wickremasinghe RG, Winslet M. Antioxidants enhance the susceptibility of colon carcinoma cells to 5-fluorouracil by augmenting the induction of the bax protein. Cancer Lett 2001; 164: 77-84.
96. Maxwell PJ, Longley DB, Latif T, i wsp. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003; 63: 4602-6.